Staging LaParoscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer
- Conditions
- Gastric CancerLymph Node Metastasis
- Registration Number
- NCT05720598
- Lead Sponsor
- Medical University of Lublin
- Brief Summary
Staging LaParscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer (POLA) study aims to investigate the safety and feasibility of ICG-guided SN retrieval in GC patients undergoing multimodal treatment. The pretreatment clinical variables potentially associated with the procedure will also be analyzed.
To the best of our knowledge, the current study is the first to evaluate the role of ICG in SN biopsy in advanced GC patients undergoing multimodal treatment.
- Detailed Description
Comprehensive lymph node assessment seems to be critical for proper treatment strategy and survival prediction, particularly in advanced GC. Recent data on the sentinel node (SN) concept in early GC has shown favorable results regarding LN detection rate and clinical status determination. Staging laparoscopy (SL) with lavage cytology provides an additional value to the clinical staging of GC, particularly in detecting occult peritoneal disease. The role of Indocyanine green (ICG) guided SN mapping in GC confirmed its technical feasibility. ICG can be safely used to identify SN, determine the surgical resection line, improve the LN harvest, and reduce noncompliance in patients undergoing D2 lymphadenectomy.
The majority of the studies focused on the aspect of the increase in LN harvest. At the same time, no data exist regarding its potential role in GC nodal staging. To the best of our knowledge, the current study is the first to evaluate the role of ICG in SN biopsy in advanced GC patients undergoing multimodal treatment.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 190
- Age ≥ 18 years
- Histologically confirmed gastric adenocarcinoma (or undifferentiated carcinoma)
- Stage II - III disease (cT2-4a, N0-3, M0) based on the pretreatment CT and 8th edition of TNM classification
- Qualification for SL by the decision of the multidisciplinary tumor board
- Written informed consent for endoscopy and SL
- Early GC (cT1N0-3M0) scheduled for endoscopic treatment by the multidisciplinary tumor board
- Previous abdominal surgery which could interfere lymphatic basin of the stomach, including previous gastrectomy, endoscopic (sub)mucosal dissection
- Distant metastasis (cM1) clinically apparent in pretreatment abdominal/pelvic CT
- Technical inability to perform endoscopic ICG injection or ICG injection beyond the submucosa
- Visual inability to identify the SN during SL
- Positive cytology (cyt+) after SL
- Other malignancies
- History of allergy to iodine agents
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method The primary endpoint of this study is the identification rate of ICG-guided SN in advanced GC patients. Up to 2 weeks after inclusion in the study, during staging laparoscopy The identification rate will allow confirmation of the safety and feasibility of ICG-guided SN biopsy during staging laparosocpy in advanced GC patients
- Secondary Outcome Measures
Name Time Method Pathological status and regression grade of the retrieved sentinel node after neoadjuvant chemotherapy Up to 2 weeks after gastrectomy, 1 month after completion of neoadjuvant chemotherapy and 3 months after initial staging laparoscopy SN retrieved during gastrectomy will undergo microscopic evaluation. The histopathological report will contain information on the character of the lymph node (benign/metastatic) and its regression grade according to Becker classification
Pathological status of the retrieved sentinel node Up to 2 weeks after staging laparoscopy SN retrieved during staging laparoscopy will undergo microscopic evaluation. The histopathological report will contain information on the character of the lymph node (benign/metastatic)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Medical University of Lublin
🇵🇱Lublin, Poland
Medical University of Lublin🇵🇱Lublin, PolandKarol RawiczPruszyński, ProfessorContact81 531 81 26karol.rawicz-pruszynski@umlub.pl